Express News | Tharimmune Announced An Option Agreement For An Exclusive License With Washington University In St. Louis For Technology Related To Multiple Hybridomas And Antibodies Directed Specifically Towards Human HER2

Moomoo 24/7Apr 23 07:35 ET

Express News | Tharimmune Inc: Obtained Rights From Washington University to Develop and Incorporate Human Her2 Directed Antibodies

Moomoo 24/7Apr 23 07:33 ET

Express News | Tharimmune Inc: Announces Option Agreement for Key Technologies for Generating Her2/Her3 Antibody Drug Conjugates (Adcs)

Moomoo 24/7Apr 23 07:33 ET

Express News | Tharimmune Forms Scientific Advisory Board To Drive Clinical-Stage Lead In Chronic Liver Disease And Early-Stage Tunable Knob Domains For Generating Antibody Drug Conjugate Biotherapeutics

Moomoo 24/7Apr 15 08:35 ET

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug conjugates and platform innovation

AccesswireApr 15 08:33 ET

Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now

Yahoo FinanceMar 6 07:00 ET